Upper, Lower Federal Courts Favor Sandoz in Amgen Biosimilar Patent Rulings

Drug Industry Daily
Sandoz triumphed over Amgen in a biosimilar patent infringement case that went from a Northern California federal court, up the ladder to the Supreme Court and back down again — following victories in both the district court and the Federal Circuit Court of Appeals this past week.

To View This Article:


Subscribe To Drug Industry Daily